Neal Shparago, DO
Rheumatology · Jackson, MSNPI 1326121542
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,809 of the $38,805 with a category attached, or 79.4%. Amgen accounts for 89.3% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $26,683 and has fallen 98.1% since, to $503 in 2025.
Across 397 payments — averaging $97.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$35K
- AbbVie$2K
- Johnson & Johnson$497
- Novartis$344
- Pfizer$283
- GSK$240
- plus $637 from 15 others
What the payments were for
- Speaking & faculty fees$30,80979%
- Travel & lodging$1,1923%
- Food & beverage$6,43817%
- Education$3661%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 159 | $34,644 |
| AbbVie | 123 | $2,160 |
| Johnson & Johnson | 21 | $497 |
| Novartis | 24 | $344 |
| Pfizer | 18 | $283 |
| GSK | 17 | $240 |
| UCB, Inc. | 13 | $196 |
| Lilly USA, LLC | 6 | $103 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Bristol Myers Squibb | 3 | $51 |
| Genentech USA, Inc. | 2 | $31 |
| Radius Health, Inc. | 1 | $29 |
| Medtronic | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Theratechnologies Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| AstraZeneca | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
| Organon | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,805 in reported general payments places this provider in the 85th percentile of 44 rheumatology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 132 | $1,019,594 |
| Enbrel SureclickEtanercept | 95 | $717,281 |
| RinvoqUpadacitinib | 72 | $492,903 |
| KrystexxaPegloticase | 12 | $351,474 |
| Enbrel MiniEtanercept | 33 | $228,261 |
| Xeljanz XrTofacitinib Citrate | 22 | $121,760 |
| ProliaDenosumab | 69 | $111,992 |
| Cimzia (2 Pack)Certolizumab Pegol | 18 | $103,908 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 17 | $81,458 |
| ActemraTocilizumab | 13 | $69,091 |
| BenlystaBelimumab | 13 | $54,916 |
| Hydroxychloroquine Sulfate | 570 | $19,422 |
| MethotrexateMethotrexate Sodium | 490 | $8,425 |
| Mycophenolate Mofetil | 60 | $5,417 |
| Leflunomide | 42 | $2,424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $2,160 | $492,90372 claims |
| AmgenKrystexxa, Prolia | $34,644 | $463,46681 claims |
| UCB, Inc.Cimzia (2 Pack) | $196 | $103,90818 claims |
| GSKBenlysta | $240 | $54,91613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 44 rheumatology providers in Mississippi.
Other rheumatology in Jackson
- Vikas MajithiaJackson$123K
- Teresa CroutJackson$16K
- Amanda FowlerJackson$13K
- Robert McMurrayJackson$12K
- Martha MagnusonJackson$3K
- Linda RockholdJackson$2K
- Nirupa MohandasJackson$1K
- Maneesh MannemJackson$1K
- Hanan IbrahimJackson$882
- Lisa MaherJackson$644
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.